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LETTERS TO THE EDITOR 
Differential Effect of Thrombolytic Therapy 
Ritchie et al. (I) recently examined limitation of infarct size, 
estimated by thallium-201 tomography, after thrombolytic therapy 
with intravenous streptokinase in a subgroup of 207 patients 
participating in the Western Washington intravenous streptokinase 
trial. The authors report that the greatest benefit of thrombolytic 
therapy occurred in patients with anterior infarction who were 
treated within 3 h after the onset of symptoms. There was little 
benefit in patients with inferior infarction or in patients with ante- 
rior infarction admitted after 3 h. These findings are in agreement 
with the subgroup analysis of the trial on intracoronary streptoki- 
nase, conducted by the Netherlands Interuniversity Cardiology 
Institute (2). In that analysis the beneficial effects of thrombolytic 
therapy on infarct size (estimated from myocardial enzyme release), 
global left ventricular function and survival were related to two 
factors: the delay between onset of symptoms and therapy and 
the extent of myocardial ischemia estimated from the total amount 
of ST segment elevation in the admission electrocardiogram 
(ECG). When the admission ECG was taken into account, infarct 
location was not related to the effect of thrombolytic therapy, 
Generally, anterior infarctions are larger than inferior wall infarc- 
tions. The effect of thrombolytic therapy appeared to be related to 
the size of the ischemic area and not as much to the site of the 
infarction. It would be of great interest to know whether similar 
effects were observed in the Western Washington intravenous 
streptokinase trial. 
It is now evident that thrombolytic therapy is useful in certain 
subgroups of patients with acute myocardial infarction and certain- 
ly not in all types of infarction. More studies, such as the report 
by Ritchie et al. (I), are needed to further delineate those patients 
who do and those who do not benefit from thrombolytic therapy, 
The use of threshold values such as anterior infarction within 
3 h after the onset of symptoms may appeal to clinicians because 
of their simplicity. However, such selection criteria for throm- 
bolytic therapy in our opinion do not reflect the more compli- 
cated clinical reality. It may be more appropriate to apply a set 
of inclusion criteria combining the delay between onset of 
symptoms and the total amount of ST segment elevation. For 
example, from the data in the trial by the Netherlands Interuniver- 
sity Cardiology Institute a so-called rule of four was developed. 
According to that rule, thrombolytic therapy is warranted in patients 
admitted within 1 h after the onset of symptoms who exhibit a sum 
of ST segment elevation in all 12 leads of 0.4 mV. In patients 
admitted between I and 2 h, the ST segment elevation should be 8 
mm, 0.8 mV; between 2 and 3 h, 0.12 mV and between 3 and 4 h, 
0+16 mV. 
MAARTEN L. SIMOONS, MD, FACC 
Thoraxcenter, on behayof the 
Study Group of The Netherlands 
Inreruniversiry Cardiology lnstirure 
Rotter&ii;, T/w Nrrherlunlls 
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Reply 
We did not collect ST segment data and cannot comment on their 
utility, and they have not been repotted in most other trials. We thus 
cannot ascertain from our data whether infarct size alone, or 
possibly other contributing coronary anatomic/physiologic features, 
can explain the differences between the anterior and inferior infarc- 
tion groups. We agree that further information is needed. 
JAMES L. RITCHIE, MD, FACC 
J. WARD KENNEDY, MD, FACC 
University of Washington 
Seattle, Washington 98108 
Dipyridamole-Induced ST Segment 
Depression by CollateraE Steal? 
Chambers and Brown (I) propose as determinants of dipyridarnole- 
induced ST segment depression an increased rate-pressure product 
and the presence of “good” collateral vessels at coronary angiog- 
raphy. They found that among patients with (visually estimated!) 
high grade stenosis (295% luminal diameter narrowing), dipyri- 
damole-induced ST segment depression was more common in 
patients with than in patients without good collateral vessels. The 
authors suggest that the collateral vessels are therefore responsible 
for the observed ST segment depression. In my view, ST segment 
depression afIer dipyrldamole infusion in the presence of collateral 
vessels indicates that the stenosis at angiography is also physiolog- 
ically signhlcant. Therefore, the relation between collateral vessels 
and ST segment depression must be an indirect one. Furthermore, it 
is difficult tojudge the functional significance of collaleral vessels by 
the coronary arteriogram and their appearance may vary consider- 
ably in time and among various injections of contrast medium in the 
same patient. 
For their methods of quantitative analysis, the authors refer to 
the excellent article of Wackers et al. (2), which deals with exercise 
thallium-201 testing. Did the authors use test-specific normal profiles 
for dipyridamole thallium-201 testing derived from subjects with low 
likelihood of coronary artery disease? 
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